NASDAQ:URGN
UroGen Pharma Ltd Stock News
$15.00
+0.0400 (+0.267%)
At Close: Mar 28, 2024
Urogen Pharma (URGN) Reports Q1 Loss, Misses Revenue Estimates
02:15pm, Tuesday, 10'th May 2022 Zacks Investment Research
Urogen Pharma (URGN) delivered earnings and revenue surprises of 8.09% and 13.16%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
01:23pm, Tuesday, 10'th May 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Pfizer Acquires Biohaven For $11B
Pfizer Inc (NYSE: PFE) will acquire Biohaven Pharmaceutical Hold
Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Tops Revenue Estimates
10:15pm, Monday, 09'th May 2022 Zacks Investment Research
Castle Biosciences, Inc. (CSTL) delivered earnings and revenue surprises of -19.40% and 6.87%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stoc
Prothena (PRTA) Reports Q1 Loss, Tops Revenue Estimates
10:35pm, Thursday, 05'th May 2022 Zacks Investment Research
Prothena (PRTA) delivered earnings and revenue surprises of 8.24% and 401.30%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Benzinga's Top Ratings Upgrades, Downgrades For April 27, 2022
02:02pm, Wednesday, 27'th Apr 2022 Benzinga
Upgrades
BTIG upgraded the previous rating for Acutus Medical Inc (NASDAQ:AFIB) from Neutral to Buy. In the fourth quarter, Acutus Medical showed an EPS of $1.00, compared to $0.89 from the year-ago
UroGen Pharma Ltd.'s (URGN) CEO Liz Barrett on Q4 2021 Results - Earnings Call Transcript
02:43pm, Monday, 21'st Mar 2022
UroGen Pharma Ltd.'s (URGN) CEO Liz Barrett on Q4 2021 Results - Earnings Call Transcript
Urogen Pharma (URGN) Reports Q4 Loss, Tops Revenue Estimates
01:15pm, Monday, 21'st Mar 2022 Zacks Investment Research
Urogen Pharma (URGN) delivered earnings and revenue surprises of -7.63% and 0.15%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Urogen Pharma (URGN) Reports Q4 Loss, Tops Revenue Estimates
10:32am, Monday, 21'st Mar 2022
Urogen Pharma (URGN) delivered earnings and revenue surprises of -7.63% and 0.15%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Scheduled For March 10, 2022
09:33am, Thursday, 10'th Mar 2022 Benzinga
Companies Reporting Before The Bell • Despegar.com (NYSE: DESP ) is expected to report quarterly loss at $0.08 per share on revenue of $110.93 million. • ProShares UltraShort Russell2000 (NYSE: TWM ) is expected to report earnings for its fourth quarter. • Vivid Seats (NASDAQ: SEAT ) is projected to report quarterly loss at $0.07 per share on revenue of $139.54 million. • LumiraDx (NASDAQ: LMDX ) is expected to report quarterly loss at $0.09 per share on revenue of $69.60 million. • Life Time Group Hldgs (NYSE: LTH ) is expected to report quarterly loss at $0.41 per share on revenue of $356.92 million. • ATRenew (NYSE: RERE ) is likely to report quarterly loss at $0.03 per share on revenue of $368.91 million. • FuelCell Energy (NASDAQ: FCEL ) is estimated to report quarterly loss at $0.05 per share on revenue of $26.73 million. • Zealand Pharma (NASDAQ: ZEAL ) is expected to report quarterly loss at $0.93 per share on revenue of $11.98 million. • Yatsen Holding (NYSE: YSG ) is projected to report quarterly loss at $0.
UroGen Pharma to Report Fourth Quarter and Full-Year 2021 Financial Results on Thursday, March 10, 2022
08:00pm, Friday, 04'th Mar 2022 Investors Urogen
Conference Call and Webcast Scheduled for Thursday, March 10, 2022 , at 10:00 AM ET PRINCETON, N.J. --(BUSINESS WIRE)--Mar. 4, 2022-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers,
UroGen Pharma to Report Fourth Quarter and Full-Year 2021 Financial Results on Thursday, March 10, 2022
03:00pm, Friday, 04'th Mar 2022
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, tod
ADC Therapeutics SA (ADCT) Reports Q4 Loss, Tops Revenue Estimates
01:25pm, Thursday, 03'rd Mar 2022 Zacks Investment Research
ADC Therapeutics SA (ADCT) delivered earnings and revenue surprises of 55.17% and 3.70%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q4 Loss, Tops Revenue Estimates
01:15pm, Tuesday, 01'st Mar 2022 Zacks Investment Research
Rhythm Pharmaceuticals, Inc. (RYTM) delivered earnings and revenue surprises of 15% and 6.26%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the s
UroGen Pharma to Participate in Panel Discussion at Cowen 42nd Annual Healthcare Conference
01:00pm, Monday, 28'th Feb 2022 Business Wire
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq:URGN), a biotech company dedicated to developing and commercializing innovative solutions to treat urothelial and specialty cancers, today announced that it will participate in a panel discussion at the upcoming virtual Cowen 42nd Annual Healthcare Conference on March 8, 2022 at 10:30am Eastern Time. A live webcast of the panel will be available on the Investors & Media section of UroGen’s website at www.urogen.com. A replay of th
Curis (CRIS) Reports Q4 Loss, Tops Revenue Estimates
10:40pm, Thursday, 24'th Feb 2022 Zacks Investment Research
Curis (CRIS) delivered earnings and revenue surprises of -15.38% and 3.26%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?